BioSpace News Archive

Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), awarded the University of Missouri School of Medicine a bridge grant for $31,500 to continue evaluating CRISPR therapy in a pre-clinical model of Duchenne

Understanding how systemic racism affects the American healthcare system and how to identify it will be the message of this year’s keynote speaker at the upcoming National Kidney Foundation’s 2021 Spring Clinical Meetings.

Artemis ABA Inc., a leading software company for Practice Management & Billing for ABA Therapy, today announced that James Vrtis has been named as Chief Executive Officer.

Control Bionics, a global assistive technology company specializing in speech generating devices, announced it is partnering with Numotion, a leading provider of Complex Rehab Technology (CRT) to offer the Control Bionics’ Trilogy product line.

Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, announced today that it has screened the first patient in ZETA-1, a Phase 2 trial to evaluate APX3330 in non-proliferative diabetic retinopathy (NPDR) and mild proliferative diabetic retinopathy (mild PDR).

ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound today announced that the Companys Chief Technology Officer will be making a presentation at the American Institute of Ultrasound in Medicine (AIUM) Annual Integrative Ultrasound Meeting on April 14 at 11:45 am ET.

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced an investigator-initiated study at Montefiore Medical Center evaluating the perioperative use of DSUVIA

Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Jaguar has entered into an amendment to the March 24, 2020 equity purchase agreement Equity Purchase Agreement with Oasis Capital, LLC

As the demand for biosimilar product information continues to grow among payers, Xcenda’s FormularyDecisions—a secure online platform that facilitates information exchange between manufacturers and healthcare decision-makers—announced the launch of a Biosimilars Hub.

Lyfebulb, a patient-empowerment platform that connects patients with industry to support user-driven innovation, and Arena Pharmaceuticals, a company focused on developing innovative therapeutics for immune-mediated conditions, invite entrepreneurs with innovative ideas and solutions to apply to the Imagining Life Without Limits - An Inflammatory Bowel Disease Innovation Challenge.